kracht en prestatie in sporters overtraining performance capacity
Conditions
Interventions
The intervention consists of a 8 week administration of capsules containing
either hesperidin or placebo (maltodextrin). Participants will be instructed to
consume two capsules each morning.
Sponsors
BioActor BV
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Healthy individuals (based on their medical history provided during a general health questionnaire) - Participants are amateur or (semi-) professional athletes in resistance or interval sports (engage in >4 hours of intense physical activity per week). - Age 18 * 35 - Experience in resistance and interval training
Exclusion criteria
Exclusion criteria: - Use of creatine supplements and/or anabolic steroids. - Allergy to test product/placebo - Allergy to citrus fruits - BMI lower than 18 or higher than 30 - Recent muscle injury in less than one month before the start of the study. - Cardiovascular complications - Use of medication that can influence the study results - Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator), in the 180 days prior to the study. - Abuse of products; alcohol (> 20 alcoholic units per week) and drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure of this study is to determine whether hesperidin supplementation for a period of 8 weeks has an effect on peak force output in the Wingate cycling test compared to placebo. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints entail the evaluation of the effect of daily administration hesperidin on sprinting times, jumping height and force, average force output, peak force output, blood lactate, anaerobic capacity, rate of force development, perceived exertion and delayed onset muscle soreness in the different exercise tests. | — |
Countries
Netherlands
Outcome results
None listed